ST. JOSEPH, Mo. (March 26, 2012) – Boehringer Ingelheim Vetmedica, Inc., (BIVI) announces that Tim Bettington has been promoted to vice president of sales and marketing for all the company’s business segments, including pet, swine, cattle and equine. In this newly created position, Bettington is responsible for the execution and success of all species business priorities. The promotion is effective April 1, 2012.
For the last two years, Bettington has been executive director of swine sales and marketing, and he will continue leading the swine organization in conjunction with his new role. Bettington joined BIVI in 2008 as senior associate director of swine marketing and was responsible for marketing several of the company’s most innovative swine vaccines on the market: Ingelvac CircoFLEX and Ingelvac MycoFLEX.
Albrecht Kissel, president and CEO of BIVI, says Bettington’s experience in the global animal health industry, including 11 years in his native Australia with Jurox Pharmaceuticals, makes him well-suited for this new position.
“Tim has served in many roles from territory manager, national product manager, national sales and marketing manager, giving him a very broad global industry perspective,” says Kissel. “During the last four years at BIVI, Tim has led the introduction of some of our newest vaccines and contributed greatly to our ability to meet the needs of our customers. As we continue to grow our portfolio of innovative products across all species, gain market share and improve our internal processes, Tim’s experience and leadership will become even more invaluable.”
Bettington is a graduate of the University of Western Sydney, Hawkesbury Campus, and has a master’s degree in marketing management from Macquarie Graduate School of Management.
Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, Mo.), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, Conn., and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
For Boehringer Ingelheim—and its employees—carrying a good share of social responsibility is an important component in its business culture. Both global commitments in social projects and properly caring for all its employees are included. Respect, equal opportunity, and the balance of career and family life form the basis for mutual cooperation. And, environmental protection and sustainability are always the main focus during any of Boehringer Ingelheim’s undertakings.
In 2010, Boehringer Ingelheim posted net sales of approximately $16.7 billion (about 12.6 billion euro) while spending almost 24% of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information, please visit: www.bi-vetmedica.com .